<DOC>
	<DOCNO>NCT00240253</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety add Symlin establish regimen insulin glargine subject type 2 diabetes achieve glycemic target .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Adding Symlin® Lantus® ( Insulin Glargine ) Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has HbA1c &gt; 7.0 % &lt; =10.5 % Has body mass index ( BMI ) &gt; =25 kg/m2 &lt; =45 kg/m2 Has receive insulin glargine 3 month prior study start stable dose 1 month prior study start If take oral antidiabetic agent , stable dose least 2 month Has previously treat Symlin/pramlintide ( participate Symlin/pramlintide clinical study ) Has receive investigational drug within 1 month screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Symlin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>insulin glargine</keyword>
</DOC>